|
| Status |
Public on May 01, 2018 |
| Title |
RNA-seq of MMTV-Neu AXL KO tumor grafts in FVB |
| Organism |
Mus musculus |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
AXL is activated by its ligand GAS6 and is expressed in triple-negative breast cancer cells. We report that AXL is also detected in HER2+ breast cancer specimens where its expression correlates with poor patients’ survival. Using murine models of HER2+ breast cancer, AXL, but not Gas6, was found essential for metastasis. We determined that AXL is required for intravasation, extravasation and growth at the metastatic site. AXL is expressed in HER2+ cancers displaying EMT signatures and contributes to sustain EMT in murine tumors. Interfering with AXL in patient-derived xenograft impaired TGF-β-induced cell invasion. Lastly, pharmacological inhibition of AXL decreased the metastatic burden of mice developing HER2+ breast cancer. Our data identify AXL as a potential co-therapeutic target during the treatment of HER2+ breast cancers to limit metastasis.
|
| |
|
| Overall design |
Differential gene expression profile between tumor grafts of AXL-/- and AXL+/+ cells in FVB mice by RNA sequencing (Illumina HiSEq 2000)
|
| |
|
| Contributor(s) |
Côté J, Goyette M |
| Citation(s) |
29719259 |
| |
| Submission date |
Aug 08, 2017 |
| Last update date |
Jul 25, 2021 |
| Contact name |
Marie-Anne Goyette |
| Organization name |
IRCM
|
| Street address |
110 av. Des Pins Ouest
|
| City |
Montreal |
| ZIP/Postal code |
H2W 1R7 |
| Country |
Canada |
| |
|
| Platforms (1) |
| GPL13112 |
Illumina HiSeq 2000 (Mus musculus) |
|
| Samples (6)
|
|
| This SubSeries is part of SuperSeries: |
| GSE102370 |
The Receptor Tyrosine Kinase AXL is Required at Multiple Steps of the Metastatic Cascade during HER2-positive Breast Cancer Progression |
|
| Relations |
| BioProject |
PRJNA397626 |
| SRA |
SRP115120 |
Less...
More...